Capmatinib

Drug Profile

Capmatinib

Alternative Names: INC-280; INCB-028060; INCB-28060

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Developer Array BioPharma; Novartis Oncology
  • Class Antineoplastics; Benzamides; Heterocyclic bicyclo compounds; Imidazoles; Quinolines; Small molecules; Triazines
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma; Hepatocellular carcinoma; Malignant melanoma; Non-small cell lung cancer
  • Phase I/II Colorectal cancer; Head and neck cancer
  • Phase I Renal cell carcinoma; Solid tumours

Most Recent Events

  • 29 Mar 2017 Novartis terminates a phase II trial in Hepatocellular carcinoma (First-line therapy, Late-stage disease) in Singapore, Thailand, Taiwan, Hong Kong and China due to difficulty to identify patients who meet the eligibility criteria of the study (NCT01737827)
  • 14 Feb 2017 Novartis announces intention to submit NDA in 2018
  • 13 Feb 2017 Novartis Pharmaceuticals suspends participant recruitment in a phase I/II trial in Head and neck cancer and Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA, Canada, Spain, France, Germany, Italy and Belgium (NCT02205398)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top